The latest financial statement is for the quarter ending 2025-10-24.
| Cash Flow | 2025-10-24 | 2025-07-25 | 2025-04-25 | 2025-01-24 |
|---|---|---|---|---|
| Net income | 1,381 | 1,047 | 1,061 | 1,303 |
| Depreciation and amortization | 745 | 748 | 840 | 684 |
| Provision for credit losses | 38 | 28 | 27 | 51 |
| Deferred income taxes | -7 | 167 | -235 | -138 |
| Stock-based compensation | 182 | 86 | 89 | 98 |
| Loss on debt extinguishment | - | - | 0 | - |
| Asset impairments and related inventory write-downs | - | - | 0 | - |
| Other, net | -8 | -159 | -296 | -112 |
| Accounts receivable, net | 214 | -288 | 249 | 3 |
| Inventories | 299 | 373 | -186 | 200 |
| Accounts payable and accrued liabilities | -182 | -598 | 366 | 550 |
| Other operating assets and liabilities | 727 | 464 | -147 | -115 |
| Net cash provided by operating activities | 925 | 1,088 | 2,528 | 2,572 |
| Acquisitions, net of cash acquired | - | - | 0 | 98 |
| Additions to property, plant, and equipment | 468 | 504 | 459 | 476 |
| Purchases of investments | 2,101 | 2,100 | 2,133 | 2,074 |
| Sales and maturities of investments | 1,948 | 2,010 | 2,240 | 1,917 |
| Other investing activities, net | -139 | 125 | 138 | 112 |
| Net cash used in investing activities | -482 | -719 | -490 | -843 |
| Change in current debt obligations, net | 753 | 649 | 0 | -1,003 |
| Proceeds from short-term borrowings (maturities greater than 90 days) | - | - | 0 | - |
| Repayments from short-term borrowings (maturities greater than 90 days) | - | - | 0 | - |
| Issuance of long-term debt | 1,747 | 0 | 0 | 0 |
| Payments on long-term debt | 1,768 | 1,162 | 0 | - |
| Dividends to shareholders | 910 | 910 | 897 | 897 |
| Issuance of ordinary shares | 160 | 95 | 108 | 168 |
| Repurchase of ordinary shares | 372 | 123 | 274 | 181 |
| Other financing activities, net | -5 | 70 | -280 | 160 |
| Net cash used in financing activities | -395 | -1,381 | -1,343 | -1,753 |
| Effect of exchange rate changes on cash and cash equivalents | -39 | 67 | 283 | -130 |
| Net change in cash and cash equivalents | 9 | -945 | 978 | -154 |
| Cash and cash equivalents at beginning of period | 1,273 | 2,218 | 1,240 | 1,394 |
| Cash and cash equivalents at end of period | 1,282 | 1,273 | 2,218 | 1,240 |
Medtronic plc (MDT)
Medtronic plc (MDT)